JPRN-jRCT2080221043未知2 期
A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
ovartis Pharma K.K.0 个研究点开始时间: 2010年3月19日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Chronic plaque-type psoriasis diagnosed for at least 6 months at time of randomization
- •-At randomization, moderate to severe psoriasis as defined by:
- •-PASI score of 12 or greater and,
- •-IGA score of 3 or greater and,
- •-Body Surface Area (BSA) affected by plaque-type psoriasis of 10% or greater At screening and randomization
排除标准
- •-Forms of psoriasis other than chronic plaque-type
- •-Drug-induced psoriasis at randomization
- •-Ongoing use of prohibited psoriasis treatments / medications at randomization.
- •Other protocol-defined inclusion/exclusion criteria may apply
研究者
相似试验
未知
3 期
Safety and efficacy of AIN457 in patients with active non-infectious uveitisJPRN-jRCT2080221051ovartis Pharma K.K.208
终止
2 期
Cemdisiran and eculizumab dose-ranging study for paroxysmal nocturnal haemoglobinuriaParoxysmal nocturnal haemoglobinuria (PNH)Haematological DisordersParoxysmal nocturnal haemoglobinuria [Marchiafava-Micheli]ISRCTN31882639niversity of Leeds9
招募中
1 期
Efficacy and Tolerability of AP707 in Patients with Chronic Back PaiChronic back painCTIS2022-502151-54-00Cannaxan GmbH558
招募中
1 期
Efficacy and Tolerability of AP707 in Patients with chronic pain due to central Neuropathy of any GenesisChronic pain due to central Neuropathy of any GenesisCTIS2022-500899-66-00Cannaxan GmbH558
招募中
1 期
Efficacy and Tolerability of AP707 in Patients with chronic Pain due to Diabetic PolyneuropathyChronic pain due to diabetic polyneuropathyCTIS2022-500897-32-00Cannaxan GmbH558